Your session is about to expire
← Back to Search
Standard-of-care treatment for Lupus Nephritis (ORCHID-LN Trial)
ORCHID-LN Trial Summary
This trial will test whether the drug guselkumab can effectively treat lupus nephritis, a kidney inflammation caused by lupus.
- Lupus Nephritis
ORCHID-LN Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowORCHID-LN Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ORCHID-LN Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this a pioneering clinical trial?
"Since the 2018 inception of Janssen Research & Development, LLC's pioneering study involving 1406 participants, Standard-of-care treatment has gained Phase 2 and 3 drug authorisation. Currently 19 trials are underway in 286 cities across 57 nations."
Are there openings for participation in this investigation?
"According to clinicaltrials.gov, this particular trial is not presently recruiting participants; the protocol was first announced on September 15th 2020 and recently edited on November 3rd 2022. However, there are currently 59 other medical studies that are actively looking for volunteers."
Are adults aged 30 and above considered to be applicable for this trial?
"The study requirements specify that applicants must be aged between 18 and 75. There is an additional 10 studies for minors and 50 specifically designed for seniors."
What criteria best qualifies participants for this clinical research?
"To qualify for this trial, prospective participants must be afflicted with lupus nephritis and situated between 18 to 75 years of age. The research team is enrolling 33 individuals in total."
Have there been prior studies utilizing the accepted medical protocol?
"Currently, 19 studies are being conducted to evaluate the efficacy of Standard-of-care treatment. Of these active clinical trials, 7 have progressed to Phase 3. While Milan and Kansas both feature a number of sites for evaluating this therapy, there is an expansive network of 2732 locations around the world running similar experiments."
Are any Canadian medical facilities carrying out this clinical investigation?
"At the moment, this experimental trial is being conducted at 5 different sites. These locations are situated in La Jolla, Los Angeles and Aurora among other areas. To reduce any travel burdens associated with participation, it is recommended to select a site nearest you."
What is the upper boundary of participants in this trial?
"Unfortunately, this trial is no longer recruiting participants. Initial postings were made on September 15th 2020 and the study was last edited on November 3rd 2022. If you're looking for other trials, there are presently 40 studies admitting patients with lupus nephritis and 19 clinical trials finding individuals to receive standard-of-care treatments."
Does the accepted best practice pose any risks to individuals?
"While there is evidence of safety, no data in regards to efficacy exists yet. Therefore its risk score falls at a moderate 2 on the 1-3 scale."
Share this study with friends
Copy Link
Messenger